A Phase 1 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Multiantigen HIV (HIV-MAG) Plasmid DNA (pDNA) Vaccine Co-administered With Recombinant Human IL-12 pDNA (GENEVAX(R) IL-12) Followed or Preceded by Recombinant Ad35-GRIN/ENV HIV Vaccine in HIV-Uninfected, Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2015
At a glance
- Drugs HIV DNA vaccine; HIV vaccine
- Indications HIV infections
- Focus Adverse reactions
- 04 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Dec 2011 New trial record